TrialMultiple sclerosis (Houndmills, Basingstoke, England)2009

Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood--brain barrier disruption in multiple sclerosis.

Bibiana Bielekova et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.